secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2026-08-04T20:05:21+00:00
Accession:  0001690585-26-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Q2 net loss $50.2M; CIDP trial 75% response; cash $1.2B
----------------------------------------------------------------

- Net loss $50.2M ($0.90/share) vs $31.6M ($0.88) in Q2 2025; R&D $48.7M, G&A $13.6M.
- Cash $1.2B as of June 30, 2026, providing runway into 2030.
- Phase 3 CAPTIVATE (CIDP) interim: 75% response rate in first 40 patients; Part B guidance by YE'26.
- Phase 3 EMERGE (gMG) initiated; top-line results expected 2H'28.
- Phase 2 MoMeNtum (MMN) enrollment completed (46 patients); top-line Dec '26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/0001690585-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001690585-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer